<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT</h2>
    <div class="badge">2025-09-15T13:09:26+00:00</div>
    <ul>
      <li>For Q2 2025, Janux reported a net loss of $33.9 million, which is an increase from the $6.0 million net loss in Q2 2024.</li>
<li>R&amp;D expenses were $34.7 million, compared to $14.9 million a year earlier, and G&amp;A expenses were $10.5 million, up from $7.8 million in Q2 2024.</li>
<li>On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target.</li>
<li>The company also announced that it received a $10 million milestone payment from Merck after the first patient was dosed in a lead collaboration program.</li>
<li>(NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential.</li>
<li>READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.</li>
<li>Both JANX007 and JANX008 are currently enrolling patients in their respective Phase 1 clinical trials.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Truist%20Initiates%20Coverage%20on%20Janux%20Therapeutics%20%28JANX%29%20with%20a%20Buy%20Rating%2C%20%24100%20PT%0A%E2%80%A2%20For%20Q2%202025%2C%20Janux%20reported%20a%20net%20loss%20of%20%2433.9%20million%2C%20which%20is%20an%20increase%20from%20the%20%246.0%20million%20net%20loss%20in%20Q2%202024.%0A%E2%80%A2%20R%26D%20expenses%20were%20%2434.7%20million%2C%20compared%20to%20%2414.9%20million%20a%20year%20earlier%2C%20and%20G%26A%20expenses%20were%20%2410.5%20million%2C%20up%20from%20%247.8%20million%20in%20Q2%202024.%0A%E2%80%A2%20On%20September%2010%2C%20Truist%20initiated%20coverage%20of%20Janux%20Therapeutics%20with%20a%20Buy%20rating%20and%20%24100%20price%20target.%0A%E2%80%A2%20The%20company%20also%20announced%20that%20it%20received%20a%20%2410%20million%20milestone%20payment%20from%20Merck%20after%20the%20first%20patient%20was%20dosed%20in%20a%20lead%20collaboration%20program.%0A%E2%80%A2%20%28NASDAQ%3AJANX%29%20is%20one%20of%20the%20best%20up%20and%20coming%20stocks%20with%20huge%20upside%20potential.%0A%E2%80%A2%20READ%20NEXT%3A%2030%20Stocks%20That%20Should%20Double%20in%203%20Years%20and%2011%20Hidden%20AI%20Stocks%20to%20Buy%20Right%20Now.%0A%E2%80%A2%20Both%20JANX007%20and%20JANX008%20are%20currently%20enrolling%20patients%20in%20their%20respective%20Phase%201%20clinical%20trials.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Ftruist-initiates-coverage-on-janux-therapeutics-janx-with-a-buy-rating-100-pt%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/truist-initiates-coverage-janux-therapeutics-130926769.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>